Beijing-based Contract Research Organization (CRO) ICE Bioscience has reportedly raised close to RMB 100 million (USD 14 million) in a Series B+ financing round. The round was led by Alwin Capital, with additional investments from EVEREST, CICC Capital, Addor Capital, and Root Venture Partners. The funds raised will be directed towards enhancing the company’s integration efforts.
ICE Bioscience’s Core Competencies and Technologies
Founded in 2010, ICE Bioscience has established a strong reputation for its capabilities and technologies in the fields of immunology and oncology, as well as cardiovascular and central nervous system (CNS) diseases. The company’s expertise in these areas positions it as a key player in the CRO market, providing valuable services to clients in the pharmaceutical and biotechnology sectors.
Expanding Integration Efforts
The proceeds from the Series B+ financing will be utilized to strengthen ICE Bioscience’s integration capabilities, which is crucial for streamlining operations and improving the efficiency of clinical research and development processes. This investment is expected to further solidify the company’s position in the competitive landscape of CROs and enhance its ability to deliver high-quality services to clients.-Fineline Info & Tech
